180 Life Sciences Corporate Media Kit

19 Synthetic CBD Analogs (SCAs) for Pain and Inflammation • Safe & non-psychoactive • Formulated to offer improved oral bioavailability (> three-fold) • Rigorously tested in clinical trials for inflammatory pain (efficacy and dosing) • Granted market approval by FDA, EMA and others • A real alternative to unregulated consumption of medical marijuana or OTC CBD (no clinical evidence, not FDA approved, unreliable composition, unpredictable dosing and safety) × Variable composition, potency, and may contain undesirable contaminants ✓ Wewill use SYNTHETIC >99.5% pure SCAs Problems with MM / OTC CBD Our Solution × Side effects can be triggered by THC (e.g. psychosis) × Little clinical data from approved drugs exist (outside of epilepsy) to determine dosing × Variable uptake and low absorption (~4 - 9%) due to lipophilic properties of CBD / CBD-like ✓ Wewill use synthetic CBD Analogs (SCAs) – no THC ✓ Planningblindedclinical trials initially inmusculoskeletal pain and arthritis ✓ Developing novel, patented ProNanoLipospheres (PNL) which enhance bioavailability • CBD and CBD-PNL administered orally to rats & plasma levels assessed over time • CBD-PNL >3x absorption compared to CBD alone • CBD-PNL safe and well tolerated • Additional methods to improve absorption are being patented under a recently completed agreement with HU (1) Cherniakov I, et al. (2017) European J of Pharm. Sci 109:21-30 Led by Marc Feldmann, key players Mechoulam, Gallily, Domb Developing proprietary compounds which aim to be: 160 140 120 100 80 60 40 20 0 0 1 2 3 4 5 6 CBD CBD-PNL Time(h) Conc.ng/ml AUC(h*ng/ml) 90+/-21 300+/-95 39+/-8 137+/-43 CBD CBD-PNL CBD-PNL Enhances Bioavailability < 3fold 1 180 Life Sciences Corp. www.180lifesciences.com Q4 2020